AGP Executive Report
Last update: an hour agoDiphtheria Alert: Australia’s worst diphtheria outbreak in decades has reached one death, with cases rising sharply since February—prompting renewed focus on vaccination coverage and boosters for travellers. Postnatal Care Funding: New Zealand has committed $34.4m to support a 3-day minimum postnatal stay, with colleges urging flexible, needs-based implementation. Psychedelic Therapy Access: Australia’s TGA has updated the Authorized Prescriber framework for prescribed psilocybin and MDMA, expanding eligible clinicians and treatment settings under a regulated model. PFAS Legal Push: Australia has launched a $1.4b lawsuit against 3M over “forever chemicals” from firefighting foam used at defence bases, seeking costs for investigation, remediation and mitigation. Workplace Safety Tech: Cannabix’s BreathLogix alcohol screening is being deployed across Australian mining, municipal and aviation sites to improve pre-access testing and compliance. Koala Health Research: A koala chlamydia vaccine program says it’s not yet testing on wild populations, but is progressing toward APVMA-approved batches and staged safety trials. Diabetes Snapshot: New international data shows Australia at 6.4% adult diabetes prevalence, underscoring the ongoing burden of a “silent” disease.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
